Toinv - You made the following statement.

"What we’ve seen from the zen3694 mCRPC trial is that zen3694 has very strong results in a few patients but not others."

I would say that the results might be stronger than you infer. Out of 24 of the Abiraterane progressors, 7 have passed Zenith's target with three still ongoing. Seven more are approximately at or passed SOC with three of them ongoing. Within the remaining 10, four are ongoing. That is 7 successful and 7 ongoing that might be successful so 14 out of 24 possibly successful.

Of the 37 progressed on Enzalutamide, six have passed Zenith's target (3 ongoing) with 5 more past SOC and ongoing. Of the other 26, twelve are ongoing. That is 6 successful and 17 more ongoing that might be successful so 23 out of 37 possibly successful. 

I don't think we want to let a few superstars taint our view of the rest as they might still be highly successful and who can guess how many more superstars might be lurking within them.